De nouvelles cibles cytokiniques dans la polyarthrite rhumatoïde : le tocilizumab et les autres inhibiteurs des cytokines

Ghita Harifi(Hôpital d'Hautepierre), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Christelle Sordet, Emmanuel Chatelus(Laboratoire National de Référence), Jacques‐Eric Gottenberg(Centre National de la Recherche Scientifique)
Revue du Rhumatisme
May 1, 2010
10.1016/s1169-8330(10)70006-5
Cited by 2

Related Papers

<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Lymphomas in Patients With Sjogren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses
|Blood|1997|346
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
|Annals of the Rheumatic Diseases|2012|207